Well-differentiated thyroid carcinoma: The role of post-operative radioactive iodine administration
Article first published online: 28 NOV 2012
Copyright © 2012 Wiley Periodicals, Inc.
Journal of Surgical Oncology
Volume 107, Issue 6, pages 665–672, 1 May 2013
How to Cite
Patel, S. S. and Goldfarb, M. (2013), Well-differentiated thyroid carcinoma: The role of post-operative radioactive iodine administration. J. Surg. Oncol., 107: 665–672. doi: 10.1002/jso.23295
- Issue published online: 16 APR 2013
- Article first published online: 28 NOV 2012
- Manuscript Accepted: 26 OCT 2012
- Manuscript Received: 13 JUN 2012
- differentiated thyroid cancer;
Post-operative management of differentiated thyroid cancer (DTC) often involves administration of radioactive iodine (RAI) for remnant ablation or adjuvant therapy. However, given the favorable prognosis associated with DTC, the risk versus benefit ratio of RAI remains unclear. RAI is associated with substantial, albeit rare side effects, including a possible increased risk of secondary malignancy and altered fertility, which must be balanced against the magnitude of benefit for decreasing recurrence and improving survival. J. Surg. Oncol. 2013;107:665–672. © 2012 Wiley Periodicals, Inc.